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OBJECTIVES To elucidate the pattern of expression of four members of the Bcl-2 family of proteins and
to correlate this with terminal deoxynucleotidyl transferase [TdT]-mediated dUTP nick end
labelling (TUNEL) and DNA fragmentation.
BACKGROUND Apoptosis has been implicated as a possible mechanism in the development of heart failure.
However, the mechanisms involved remain unclear.
METHODS We have studied the expression of four members of the Bcl-2 family that are involved in the
regulation of apoptosis and analyzed DNA fragmentation as a marker of apoptosis and as a
biochemical criterion to distinguish between apoptosis and necrosis in dilated cardiomyop-
athy (DCM), ischemic heart disease (IHD) and normal donors.
RESULTS Western blot analysis and immunocytochemistry of the proapoptotic and antiapoptotic Bcl-2
proteins demonstrated significantly higher levels of all these proteins in the diseased groups
compared with normal donors. Additionally, Bax was significantly higher in the IHD group
compared with DCM. Terminal deoxynucleotidyl transferase [TdT]-mediated dUTP nick
end labelling analysis demonstrated a significantly higher percentage of TUNEL-positive
cells in the diseased groups compared with the control. Genomic DNA extraction of
ventricular myocardial tissue showed no demonstrable DNA laddering for any of the groups.
CONCLUSIONS The significant increases in the levels of the proapoptotic proteins Bak and Bax and the higher
percentage of TUNEL-positive cells in both diseased groups suggests the presence of ongoing
apoptosis. However, increases in the antiapoptotic proteins, Bcl-2 and Bcl-xL, suggest a
possible concommitant, compensatory antiapoptotic mechanism in patients with heart failure.
(J Am Coll Cardiol 2000;35:1769–77) © 2000 by the American College of Cardiology
In heart failure myocardial cell loss had been traditionally
attributed to tissue necrosis based on the morphological
observation of dead myocytes and replacement fibrosis.
However, it has now been accepted that apoptosis occurs in
human hearts under various pathologic conditions including
acute myocardial infarction (1–4), arrhythmogenic right
ventricular dysplasia (5), complete heart block (6), long QT
syndrome (7,8), Uhl’s anomaly (9), atherosclerosis (10),
restenosis (11) and also in end-stage dilated and ischemic
cardiomyopathy (12,13) and end-stage hypertrophic cardio-
myopathy (14). However, these latter reports have relied
heavily on the techniques of TUNEL (terminal deoxynu-
cleotidyl transferase [TdT]-mediated dUTP nick end label-
ling) and DNA fragmentation.
Apoptosis is a complex, multistep, biochemical process
that involves a decision step, which is mediated, in part, by
the Bcl-2 family of proteins and an execution phase, which
is mediated by the caspases. The Bcl-2 family of proteins
consists of anti- and proapoptotic members, and the Bcl-2
protooncogene (15,16) suppresses apoptosis. Bcl-x encodes
for two important protein isoforms by alternate splicing, of
which the longer, Bcl-xL, inhibits apoptosis, whereas the
shorter form, Bcl-xS, facilitates apoptosis by acting as a
dominant inhibitor of Bcl-2 and Bcl-xL (17).
Bax (Bcl-2 associated X protein) and Bak (Bcl-2 homol-
ogous antagonist/killer) have powerful death-promoting
abilities and primarily enhance apoptotic cell death after an
appropriate stimulus (18–21). The ability of Bax to block
apoptosis is critically dependent on the ratio of Bcl-2 to Bax.
When Bcl-2 is in excess, Bax/Bcl-2 heterodimers are
formed, and cells are protected. However, when Bax pre-
dominates, Bax homodimers are formed, and cells are
susceptible to programmed cell death (22). In general,
susceptibility of a cell to undergo apoptosis is regulated,
in part, by the relative levels and competing dimerizations
between the Bcl-2 family members. The Bcl-2 protein
has been shown to bind to Bak, Bax, Bcl-xL, Bcl-xS,
mcl-1, Bad and itself (18,23–25), and Bcl-xL similarly
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interacts with Bax, Bak, Bcl-2, Bcl-xS, mcl-1 and Bad
(21).
To gain further insights into the possible biochemical/
cellular pathways that lead to apoptosis, we have investi-
gated the expression of four members of the Bcl-2 family of
proteins: two antiapoptotic, Bcl-2 and Bcl-xL and two
apoptotic, Bax and Bak. Additionally the TUNEL assay
was used to assess the degree of apoptosis, and DNA
fragmentation was used as a marker of apoptosis and as a
biochemical criteria to distinguish between apoptosis and
necrosis in heart failure.
MATERIALS AND METHODS
Patients. The study group consisted of 20 patients with
dilated cardiomyopathy (DCM) and 27 patients with isch-
emic heart disease (IHD). Details are given in Table 1. To
confirm the diagnosis, all patients underwent an assessment
that included a medical history, clinical investigations,
two-dimensional M-mode and Doppler echocardiography,
cardiac catheterization, evaluation of hemodynamic func-
tion and coronary arteriography for the DCM group.
Ethical permission was obtained from Hillingdon Health
Authority Ethics Committee.
Twenty-seven normal donors (23 men, 4 women, [mean
age 38, age range 15–58 years]) without any cardiac com-
plications were used as a control group for comparative
purposes.
Tissue. Myocardial tissue from the left ventricle was ex-
cised distal from the site of any myocardial infarcts from the
diseased group of patients. Control myocardial specimens
from the left atrium (n 5 10) and left ventricle (n 5 17)
were obtained from 27 normal cardiac transplant donors
without any heart disease or cardiac complications. No
differences were detected in the Bcl-2 family of proteins
between atrial and ventricular samples; hence, these control
samples were grouped together.
SDS-PAGE and Western blotting. Total protein ho-
mogenates (100 mg) were denatured and separated on 12%
T SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel
electrophoresis) gels and transferred to nitrocellulose (Hy-
bond C, Amersham, United Kingdom). Nitrocellulose
membranes were probed using primary antibodies against
the Bcl-2 family members (Santa Cruz, California). Visu-
alization of the protein bands was accomplished using
SuperSignal Ultra chemiluminescence substrate (Pierce).
Stripping membranes. For probing, tubulin blots were
incubated in str ipping solution (100 mmol/L
2-mercaptoethanol, 2% w/v SDS, 62.5 mmol/L Tris Chlo-
ride, pH 6.7) for 30 min at 50°C and then probed using
antitubulin (Sigma, Dorset, United Kingdom).
Densitometry. The level of expression of the various Bcl-2
family of antibodies was standardized to tubulin reactivity in
each respective lane and quantitated by laser densitometry,
which was carried out using the QUANTITY ONE soft-
ware (Bio-Rad laboratories, California) on a Sun Sparc
station.
Immunocytochemistry. Frozen sections (5–6 mm) were
stained with PBS, a mouse irrelevant primary antibody and
rabbit serum as negative controls and alpha-sarcomeric actin
as a positive control. Antibodies of the Bcl-2 family were
incubated on serial sections with a second layer of biotin-
ylated rabbit antimouse or swine antirabbit immunoglobu-
lins (Dako, Cambridgeshire, United Kingdom) followed by
Extravidin peroxidase complex (Dako). Reactivity was de-
tected using diaminobenzidine tetrahydrochloride (25 mg/
ml) and hydrogen peroxide (0.01% w/v). All slides were
counterstained in Mayer’s hemotoxylin. The reactivity of
the different proteins was graded according to their intensity
within the entire section as negative, weak, moderate or
strong staining.
TUNEL assay. The TUNEL assay was performed using
the Apoptag kit (S7110-KIT, Oncor). For negative controls
the TdT enzyme was omitted. DNAse 1 treated sections
were used as positive controls. DNAse 1 (1.0 mg/ml) was
dissolved in DN Buffer (30 mM Trizma base, pH 7.2, 4
mmol/L MgCl2, 0.1 mmol/L DTT) and applied for
10 min. Serial sections from each sample were used for a
Abbreviations and Acronyms
DCM 5 dilated cardiomyopathy
IHD 5 ischemic heart disease
TUNEL 5 terminal deoxynucleotidyl transferase
[TdT]-mediated dUTP nick end labelling
Table 1. Details of the Study Patients
DCM (n 5 20) IHD (n 5 27)
Men:Women 18:2 25:2
Mean age
(range)
42 (22–64) 49 (26–62)
Mean LVEDD 70.64 (59–90.9) 68.8 (58.5–84.2)
Mean LVESD 62.8 (51.4–81.8) 57.8 (50–83)
Mean fractional
shortening
10.6% (6–20%) 14.2% (7–19%)
Mean ejection
fraction
22% (10–40%) 24% (12–37%)
NYHA Class
3:4
16:4 20:7
Diuretics 20 21
ACE inhibitors 16 19
Inotropes 4 6
Digoxin 10 13
Nitrates 4 11
Beta-blockers 4 0
ACE 5 angiotensin-converting enzyme; DCM 5 dilated cardiomyopathy; IHD 5
ischemic heart disease; LVEDD 5 left ventricular end diastolic dimension; LVESD
5 left ventricular end systolic dimension; NYHA 5 New York Heart Association.
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Figure 1. (A) Top panel shows the expression of Bcl-2 in myocardial samples: donor (lanes 1–3), IHD (lanes 4–6) and DCM (lanes
6–10). The number at the left indicates MW in kD and lower band demonstrates tubulin reactivity as a marker of equal loading. Bottom
panel shows the spread and the mean levels of Bcl-2 (indicated by the horizontal line) in donor, IHD and DCM. *p , 0.05. (B) Top
panel shows the expression of Bcl-xL in myocardial samples: donor (lanes 1–3), IHD (lanes 4–6) and DCM (lanes 6–10). The number
at the left indicates MW in kD, and lower band demonstrates tubulin reactivity as a marker of equal loading. Bottom panel shows the
spread and the mean levels of Bcl-xL (indicated by the horizontal line) in donor, IHD and DCM. *p , 0.05. (C) Top panel shows the
expression of Bax in myocardial samples: donor (lanes 1–3), IHD (lanes 4–6) and DCM (lanes 6–10). The number at the left indicates
MW in kD, and lower band demonstrates tubulin reactivity as a marker of equal loading. Bottom panel shows the spread and the mean
levels of Bax (indicated by the horizontal line) in donor, IHD and DCM. *p , 0.05. (D) Top panel shows the expression of Bak in
myocardial samples: donor (lanes 1–3), IHD (lanes 4–6) and DCM (lanes 6–10). The number at the left indicates MW in kD, and lower
band demonstrates tubulin reactivity as a marker of equal loading. Bottom panel shows the spread and the mean levels of Bak (indicated
by the horizontal line) in donor, IHD and DCM. *p , 0.05. DCM 5 dilated cardiomyopathy; IHD 5 ischemic heart disease.
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negative, a positive, TUNEL and also stained with mouse
antihuman alpha-sarcomeric actin (1/50) (Sigma, Dorset,
United Kingdom) to identify myocytes.
The number of TUNEL positive myocytes was counted
in the entire section of each sample. In addition, the number
of myocytes in the entire section was calculated using the
Lucia quantitative package.
DNA extraction. Genomic DNA was extracted from all
samples using the QIAamp Tissue kit (Qiagen). The DNA
was electrophoresed through a 0.8% agarose gel containing
a 1:1000 dilution of SYBR Green I DNA stain (Flowgen,
Staffordshire, United Kingdom). Genomic DNA from
TNF-alpha treated U937 cells was used as an apoptotic
DNA control. The DNA was visualized using a Storm
Image 860 System (Molecular Dynamics, Amersham,
United Kingdom).
Data analysis. A Kruskal-Wallis test for one way analysis
of variance on ranks followed by the Dunn’s test was used as
a multiple-comparison procedure for all pairwise compari-
sons against the control group, and the Fisher’s Exact test
was used to compare the numbers of patients after immu-
nocytochemical analysis. A p value of ,0.05 was considered
statistically significant.
RESULTS
Western analysis and protein quantitation for Bcl-2
family members. Low levels of Bcl-2 (Fig. 1A), Bcl-xL
(Fig. 1B), Bak (Fig. 1C) and Bax (Fig. 1D) were detected in
the donor samples; however, higher levels were seen in the
diseased groups. The Bcl-xS/L antibody detects both the
short, proapoptotic Bcl-xS (24 kD), and the long, anti-
apoptotic Bcl-xL (30 kD), form of Bcl-x and, consistently,
bands could not be detected for Bcl-xS.
Both IHD and DCM patients demonstrated significantly
(p , 0.05) increased levels of Bcl-2, Bcl-xL, Bak and Bax
compared with the donors, and, in addition, the IHD group
demonstrated a significant increase in Bax above the DCM
group (Table 2, Fig. 1D).
Immunocytochemistry. Immunocytochemistry was car-
ried out on 12, 16 and 18 donor, IHD and DCM
samples, respectively. The pattern of expression of the
various members of the Bcl-2 family mirrored that seen
by Western blotting in that the donors showed low
expression of all the Bcl-2 family of proteins, and their
expression was increased in the diseased groups (Table 3,
Fig. 2). Bcl-2 staining was generally very weak, uniform
and localized within myocytes, not endothelial cells, in all
the samples analyzed (Fig. 2, A and B). Bcl-xL staining
was generally weak and uniform in all the samples
although moderate staining was seen in isolated, focal
regions. The staining, which was cytoplasmic, was local-
ized to the myocytes, not endothelial cells, and some
nuclear staining was observed (Fig. 2, C and D).
Bak staining was generally moderate in the samples.
Significantly more patients with IHD, but not with DCM,
demonstrated moderate staining for Bak compared with the
donors. The moderate to strong staining was localized to
distinct, single myocytes surrounded by negative myocytes.
In the diseased tissues, weak Bak staining was seen over the
entire section with stronger expression in focal regions.
Endothelial staining, especially of small vessels, was also
seen (Fig. 2, E and F). Bax staining was not uniform over
the sections, but varying intensities of Bax staining could be
seen in focal patches, i.e., some focal staining was much
darker than staining in other focal regions. Significantly
more patients with IHD and DCM demonstrated strong
Bax staining compared with the donors; however, there was
no significant difference between the diseased groups. Some
nuclei of myocytes and some endothelial cells lining small
vessels were also positive for Bax staining. The Bax antibody
provided the strongest staining patterns in the diseased
tissues (Fig. 2, G and H).
TUNEL. The TUNEL assay was performed on nine
donor, seven IHD and nine DCM samples. In all the
Table 2. Quantitation of the Bcl-2 Family of Proteins After
Western Immunoprobing
Donors IHD DCM
Bcl-2 0.97 3.57 (3 3.68)* 5.17 (3 5.35)*
Bcl-xL 2.45 4.52 (3 1.84)* 4.72 (3 1.92)*
Bak 1.88 4.16 (3 2.21)* 3.20 (3 1.70)*
Bax 1.99 8.65 (3 4.35)# 5.73 (3 2.87)*
*p , 0.05 compared with donors; #p , 0.05 compared with donors and DCM.
Number in () denotes -fold increase compared with donors.
DCM 5 dilated cardiomyopathy; IHD 5 ischemic heart disease.
Table 3. Grading of the Bcl-2 Family of Proteins After Immunocytochemistry
N
Donors (n 5 12) IHD (n 5 16) DCM (n 5 18)
W M S W M S W M S
Bcl-2 6 (50) 4 (33.3) 2 (16.7) — 12 (75) 4 (25) — 13 (72) 5 (28) —
Bcl-xL — 10 (83) 2 (17) — 9 (56) 7 (44) — 13 (72) 5 (28) —
Bak — 3 (25) 6 (50) 3 (25) — 16 (100)* — 4 (22) 13 (72) 1 (6)
Bax — 3 (25) 7 (58) 2 (17) — 7 (44) 9 (56)* 4 (22) 5 (28) 9 (50)*
*p , 0.05 compared with the donors.
DCM 5 dilated cardiomyopathy; IHD 5 ischemic heart disease; M 5 moderate; N 5 negative; S 5 strong; W 5 weak staining.
Numbers in () represent percentages.
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negative controls, where TdT was omitted, no positive
reactivity was detected (Fig. 3A), and sections treated with
DNAse 1 as a positive control showed positive staining of
all the nuclei (Fig. 3B). Apoptotic cells were not seen
uniformly across sections but were randomly scattered. In
situ end labelling with TUNEL was performed in combi-
nation with staining for alpha-sarcomeric actin. This con-
firmed the identity of the TUNEL-positive cell as myocytic.
Terminal deoxynucleotidyl transferase [TdT]-mediated
dUTP nick end labelling positivity was predominantly
confined to myocytes although occasional endothelial cells
and leukocytes within vessels were seen as TUNEL positive
within some sections from all groups.
In 2/9 donor samples no TUNEL positive myocytes were
seen. In the remaining seven donor samples, very few
myocytes stained positive, ranging from one to six TUNEL
positive myocytes within the entire section. The percentage
of TUNEL-positive cells in the donor samples was (7.1 3
1023) (66.8 3 1023). The IHD and DCM samples
demonstrated higher percentages of TUNEL-positive
Figure 2. Transverse sections of myocardial tissue showing Bcl-2 reactivity in donor (A) and in DCM (B), Bcl-xL reactivity in donor (C)
and in DCM (D), Bak in donor (E) and in IHD (F) and Bax in donor (G) and in IHD (H). Original magnification 3400. DCM 5
dilated cardiomyopathy; IHD 5 ischemic heart disease.
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cells with values of 49 3 1023 (659 3 1023) and 30 3
1023 (627 3 1023), respectively (Table 4). Both dis-
eased groups demonstrated significantly higher percent-
ages of TUNEL-positive cells (p , 0.05) with a 7.0- and
a 4.2-fold increase in TUNEL positivity respectively;
however, there was no significant difference between the
two diseased groups.
DNA fragmentation. There was no detectable DNA frag-
mentation in any of the samples as assessed by laddering on
agarose gels although in three diseased samples, very faint
ladders could be discerned. Some of the diseased samples
demonstrated a degree of smearing indicative of necrosis
(Fig. 4).
DISCUSSION
This study demonstrates, for the first time, significantly ele-
vated levels of four of the Bcl-2 family members in IHD and
DCM patients compared with donor samples. Significant
increases were seen in the proapoptotic Bax and Bak and also
in the antiapoptotic Bcl-2 and Bcl-xL proteins in the IHD and
the DCM patients compared with the donors. A significant
increase in the expression of the apoptotic proteins Bak and
Bax has not previously been reported in heart failure. However,
we can confirm the findings of Olivetti et al. (12) who
demonstrated a 2.4-fold increase in Bcl-2 in patients with heart
failure. Our results demonstrated a 3.7- and 5.35-fold increase
(mean 4.52) in the levels of Bcl-2 in patients with IHD and
DCM, respectively.
Using immunocytochemistry we demonstrated that the
pattern of expression of Bcl-2 proteins was lower in the
donor samples and stronger in the diseased tissue. Positive
reactivity was restricted to myocytes using Bcl-2 and Bcl-xL;
however, endothelial cells as well as myocytes stained
positive using antibodies reactive with the apoptotic pro-
teins, Bak and Bax.
Terminal deoxynucleotidyl transferase [TdT]-mediated
dUTP nick end labelling staining provides valuable infor-
mation about the tissue distribution and, in combination
with cell specific markers, the cell types undergoing cell
Figure 3. (A) Negative TUNEL reactivity, (B) positive TUNEL DNAse 1 treated control, (C) TUNEL positive reactivity (green) in a
DCM sample, (D) propidium iodide (PI) staining (red) of section C, (E) double exposure of section C and D showing a myocyte that
is positive for TUNEL and for PI (orange) and (F) alpha-sarcomeric actin staining of a serial section of C. DCM 5 dilated
cardiomyopathy; TUNEL 5 terminal deoxynucleotidyl transferase [TdT]-mediated dUTP nick end labelling.
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death, but without electron microscopy, TUNEL positivity
may be ascribed as necrosis. Recently Kanoh et al. (26) have
demonstrated that TUNEL-positive myocytes are living
cells with increasing activity of DNA repair, which puts
greater emphasis on using a number of techniques to
recognise apoptosis.
The percentage of TUNEL positive cells was significantly
higher in the IHD and DCM patients compared with the
donor samples, but there was no significant difference
between the two diseased groups. The TUNEL data cor-
related well with the Western data where there was a
significantly higher expression of the apoptotic proteins,
Bak and Bax. Bearing in mind that the apoptotic cycle can
be as rapid as 6 h to 24 h, such high percentages of TUNEL
positive cells would imply that the loss of viable myocardial
cells could potentially be considerable over a year. In our
clinical samples of heart failure, no DNA laddering was
evident, as apoptotic myocytes were detected in single,
isolated cells, and these were extremely infrequent. This lack
of DNA laddering is ascribed to the low level of TUNEL
positive cells within a heterogeous piece of tissue. This
result differs from that of others where DNA laddering was
detected in all diseased samples (12) and only in patients
with DCM and not in those with ICM (13).
Mechanisms of apoptosis in heart failure. The mecha-
nisms of apoptosis in IHD and DCM have yet to be clearly
elucidated. Apoptosis and necrosis in heart failure may be
induced by the same agents, with the type of cell death
being dependent on the severity of the insult. Many factors,
known or suspected to be present in the failing myocardium,
have been shown to stimulate apoptosis in a variety of cells
as well as cardiac myocytes. Such factors include inflamma-
tory cytokines, reactive oxygen species, nitric oxide, hypoxia,
reperfusion, growth factors and mechanical stretch (27). Of
these, hypoxia has received considerable interest, especially
with regard to IHD, as demonstrated by exposure of
cultured neonatal rat cardiomyocytes to hypoxia, which
induced apoptosis (28,29).
In addition, all patients were receiving several drugs for
heart failure including angiotensin-converting enzyme in-
hibitors, digoxin, diuretics, inotropes and beta-adrenergic
blocking agents. Their role in the induction process of
apoptosis cannot be excluded, especially with regard to
beta-adrenergic agonists, which have been associated with
cardiac toxicity (30). Norepinephrine has also been shown
to stimulate apoptosis in ventricular myocytes (31).
Although the etiology of DCM remains unknown, in-
creasing evidence exists for this syndrome being a sequela of
acute viral myocarditis, and an immunologic etiology has
been substantiated by the presence of circulating autoanti-
bodies. Several different viruses have been shown to act as
triggers of apoptosis (32), and recent reports have demon-
strated the ability of autoantibodies to induce apoptosis and,
thereby, to have pathological significance (33,34).
Figure 4. Visualization of genomic DNA extractions of myocar-
dial tissue from donor (lanes 7 and 12), IHD (lanes 8–11) and
DCM (lanes 1–6) patients using SYBR green I DNA staining. In
lane 10 the beginnings of a ladder can be seen. L 5 1kb DNA
ladder markers; P 5 apoptosis positive control.
Table 4. Quantitation of TUNEL
Tissue sample
No. TUNEL
Positive
Myocytes
Total No.
of Myocytes
% TUNEL
1ve Cells
Donor
1 0 25,100 0
2 3 38,100 0.007
3 2 18,200 0.006
4 4 20,600 0.020
5 0 27,800 0
6 2 20,700 0.010
7 1 46,500 0.0021
8 6 40,100 0.015
9 2 50,300 0.004
Mean Donor 0.0071 6 0.0068
IHD
1 20 20,200 0.100
2 15 19,400 0.077
3 2 40,500 0.005
4 5 11,400 0.044
5 1 41,700 0.0024
6 7 30,500 0.023
7 2 21,100 0.0095
Mean IHD 0.049 6 0.059*
DCM
1 5 20,000 0.022
2 1 12,100 0.0083
3 7 13,800 0.050
4 5 13,200 0.038
5 1 10,100 0.010
6 14 21,700 0.064
7 17 22,500 0.075
8 1 14,500 0.0069
9 1 43,300 0.0023
Mean DCM 0.030 6 0.027*
*Represents p , 0.05 compared with the donors.
DCM 5 dilated cardiomyopathy; IHD 5 ischemic heart disease; TUNEL 5
terminal deoxynucleotidyl transferase [TdT]-mediated dUTP nick end labelling.
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The role of Bcl-2 family members. Although the mech-
anism of action of the Bcl-2 family members has not been
clearly defined, there is increasing evidence that these
proteins can function as channels (35–37) for ions, proteins,
or both, and as adaptor or docking proteins. As docking
proteins they may pull other proteins, like apoptotic pro-
tease activating factor-1 (38), out of the cytosol, either
sequestering them to the membrane alongside Bcl-2 (and
probably inactivating them) (39) or targeting them for
interactions with other membrane associated proteins.
Bcl-xL indirectly binds pro-FLICE (fas associated death-
domain-like interleukin-1 beta converting enzyme)
(caspase-8) (40) raising the probability that Bcl-xL prevents
the activation of caspases by sequestering procaspases.
Proapoptotic members (Bax) may interfere with channel
formation, and it has been shown that Bcl-2 binds to Bax
and blocks those channels (37), suggesting an association
with the increase in mitochondrial permeability transition
during apoptosis. This “megapore” opening results in the
generation of oxygen free radicals, dumping of stored Ca21
and the release of apoptogenic protease activators (cyto-
chrome c and apoptosis-inducing factor [AIF]) into the
cytosol in order to activate the caspases (41). Bcl-2 blocks
the activation of caspases (42–44), probably by preventing
the cell death-induced loss of mitochondrial membrane
potential (45,46) and prevents the release of mitochondrial
cytochrome c which, along with another cytoplasmic factor,
activates caspase-3 (47,48).
This study demonstrates for the first time significant
increases in two proapoptotic proteins, Bax and Bak, in
patients with heart failure. Recently Narula et al. (49) have
demonstrated the release of cytochrome c from mitochon-
dria in patients with heart failure, and elevated levels of Bax
and Bak may mediate this release, as it has been demon-
strated that Bax and Bak accelerate the opening of voltage-
dependent anion channel (50). The significant increases in
the levels of these proapoptotic proteins, as demonstrated by
Western blotting and immunocytochemistry, and the pres-
ence of increased numbers of TUNEL positive myocytes,
suggests the presence of ongoing apoptosis. The absence of
any demonstrable DNA laddering suggests that the level of
apoptosis is very low but, considering the rate of the
apoptotic cycle, over time this may prove to be significant
enough to impair cardiac function. The increases of the
antiapoptotic proteins may suggest the presence of a com-
pensatory antiapoptotic mechanism in the diseased group of
patients. Increasing evidence suggests that apoptosis is
responsible, at least in part, for the progression of heart
failure and the chronic loss of left ventricular function and
mass. Whether increased apoptosis is the primary cause of
heart failure or is secondary to an as yet unknown process
remains to be elucidated. This loss of myocardial cells
underlies the clinical manifestation of heart failure, and the
success of any therapeutic intervention will depend heavily
on a clear understanding of the mechanism of this cell loss.
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